New research from Duke and Yale universities shows added flavorings in e-cigarettes or vaping devices react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.
Scientists at Scripps Research have successfully tested a potential new smoking-cessation treatment in rodents.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria. Every treated mouse survived. The breakthrough study, published in Scientific Reports, suggests infections in humans might be cured the same way.
Treatment quickly reduced the animals' motivation to take nicotine, reversed their signs of nicotine dependence, and kept them from relapsing when they were given access to nicotine again.
Purdue University researchers, including chemistry professor and Nobel Prize winner Ei-ichi Negishi, have developed technology to create a new chemical process to synthesize drug-like molecules with ultra-high purity.
Yale researchers have developed a way to target RNA with small-molecule drugs, creating a new method for tapping into a vast number of biological mechanisms critical to metabolism and gene expression.
Chemists at The Ohio State University have developed a new and improved way to generate molecules that can enable the design of new types of synthetic drugs.
Potentially harmful and undeclared pharmaceuticals were identified in more than 700 over-the-counter dietary supplements in an analysis of US Food and Drug Administration warnings from 2007 through 2016.
A study of liver cells exposed to the common painkiller acetaminophen found a novel mechanism for the drug's toxicity at high doses. Researchers say a protein modification called glutathionylation, kicked off by acetaminophen treatment, impairs liver cell mitochondria.
In multiple sclerosis, a defective response of the body's own immune system leads to brain tissue damage. Gastrointestinal microbiota could play a far greater role in the pathogenesis of the disease than previously assumed, researchers at the University of Zurich have now found.